Thomas Nerreter (T Nerreter)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 14

Top Topics

Tyrosine Kinase

Multiple Myeloma

Chronic Lymphocytic Leukemia

Top Venues

Nature communications

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Florian Märkl, Christoph Schultheiß, Murtaza Ali, Shih-Shih Chen, Marina Zintchenko, Lukas Egli, Juliane Mietz, Obinna Chijioke, Lisa Paschold, Sebastijan Spajic, Anne Holtermann, Janina Dörr, Sophia Stock, Andreas Zingg, Heinz Laubli, Ignazio Piseddu, David Anz, Marcus Dühren-von Minden, Tianjiao Zhang, Thomas Nerreter, Michael Hudecek, Susana Minguet, Nicholas Chiorazzi, Sebastian Kobold, Mascha Binder
Mutation-specific CAR T cells as precision therapy for IGLV3-21 R110 expressing high-risk chronic lymphocytic leukemia. Nature communications 15 (1) (2024)
Florian Märkl, Christoph Schultheiß, Murtaza Ali, Shih-Shih Chen, Marina Zintchenko, Lukas Egli, Juliane Mietz, Obinna Chijioke, Lisa Paschold, Sebastijan Spajic, Anne Holtermann, Janina Dörr, Sophia Stock, Andreas Zingg, Heinz Laubli, Ignazio Piseddu, David Anz, Marcus Dühren-von Minden, Tianjiao Zhang, Thomas Nerreter, Michael Hudecek, Susana Minguet, Nicholas Chiorazzi, Sebastian Kobold, Mascha Binder
Mutation-specific CAR T cells as precision therapy for IGLV3-21 R110 expressing high-risk chronic lymphocytic leukemia. Nature communications 15 (1) (2024)
Florian Märkl, Christoph Schultheiß, Murtaza Ali, Shih-Shih Chen, Marina Zintchenko, Lukas Egli, Juliane Mietz, Obinna Chijioke, Lisa Paschold, Sebastijan Spajic, Anne Holtermann, Janina Dörr, Sophia Stock, Andreas Zingg, Heinz Laubli, Ignazio Piseddu, David Anz, Marcus Dühren-von Minden, Tianjiao Zhang, Thomas Nerreter, Michael Hudecek, Susana Minguet, Nicholas Chiorazzi, Sebastian Kobold, Mascha Binder
Mutation-specific CAR T cells as precision therapy for IGLV3-21 R110 expressing high-risk chronic lymphocytic leukemia. Nature communications 15 (1) (2024)
Florian Märkl, Christoph Schultheiß, Murtaza Ali, Shih-Shih Chen, Marina Zintchenko, Lukas Egli, Juliane Mietz, Obinna Chijioke, Lisa Paschold, Sebastijan Spajic, Anne Holtermann, Janina Dörr, Sophia Stock, Andreas Zingg, Heinz Laubli, Ignazio Piseddu, David Anz, Marcus Dühren-von Minden, Tianjiao Zhang, Thomas Nerreter, Michael Hudecek, Susana Minguet, Nicholas Chiorazzi, Sebastian Kobold, Mascha Binder
Mutation-specific CAR T cells as precision therapy for IGLV3-21 R110 expressing high-risk chronic lymphocytic leukemia. Nature communications 15 (1) (2024)
Vera Nickl, Juliana Eck, Nicolas Goedert, Julian Hübner, Thomas Nerreter, Carsten Hagemann, Ralf-Ingo Ernestus, Tim Schulz, Robert Carl Nickl, Almuth Friederike Keßler, Mario Löhr, Andreas Rosenwald, Maria Breun, Camelia Maria Monoranu
Characterization and Optimization of the Tumor Microenvironment in Patient-Derived Organotypic Slices and Organoid Models of Glioblastoma. Cancers 15 (10) (2023)
Michelle Seif, Tamara Katharina Kakoschke, Frank Ebel, Marina Maria Bellet, Nora Trinks, Giorgia Renga, Marilena Pariano, Luigina Romani, Beeke Tappe, David Espie, Emmanuel Donnadieu, Kerstin Hünniger, Antje Häder, Markus Sauer, Diane Damotte, Marco Alifano, Philip Lewis White, Matthijs Backx, Thomas Nerreter, Markus Machwirth, Oliver Kurzai, Sabrina Rebecca Prommersberger, Hermann Einsele, Michael Hudecek, Juergen Loeffler
CAR T cells targeting <i>Aspergillus fumigatus</i> are effective at treating invasive pulmonary aspergillosis in preclinical models. Science translational medicine 14 (664) (2022)
Maik Luu, Zeno Riester, Adrian Baldrich, Nicole Reichardt, Samantha Yuille, Alessandro Busetti, Matthias Klein, Anne Wempe, Hanna Leister, Hartmann Raifer, Felix Picard, Khalid Muhammad, Kim Ohl, Rossana Romero, Florence Fischer, Christian A Bauer, Magdalena Huber, Thomas M Gress, Matthias Lauth, Sophia Danhof, Tobias Bopp, Thomas Nerreter, Imke E Mulder, Ulrich Steinhoff, Michael Hudecek, Alexander Visekruna
Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer. Nature communications 12 (1) (2021)
Estefanía García-Guerrero, Ralph Götz, Sören Doose, Markus Sauer, Alfonso Rodríguez-Gil, Thomas Nerreter, K Martin Kortüm, José A Pérez-Simón, Hermann Einsele, Michael Hudecek, Sophia Danhof
Publisher Correction: Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. Leukemia (2021)
Anna Christina Dragon, Katharina Zimmermann, Thomas Nerreter, Deborah Sandfort, Julia Lahrberg, Stephan Klöß, Christina Kloth, Caroline Mangare, Agnes Bonifacius, Sabine Tischer-Zimmermann, Rainer Blasczyk, Britta Maecker-Kolhoff, Barbara Uchanska-Ziegler, Hinrich Abken, Axel Schambach, Michael Hudecek, Britta Eiz-Vesper
CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation. Journal for immunotherapy of cancer 8 (2) (2021)
Katrin Mestermann, Theodoros Giavridis, Justus Weber, Julian Rydzek, Silke Frenz, Thomas Nerreter, Andreas Mades, Michel Sadelain, Hermann Einsele, Michael Hudecek
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Science translational medicine 11 (499) (2020)
Estefanía García-Guerrero, Ralph Götz, Sören Doose, Markus Sauer, Alfonso Rodríguez-Gil, Thomas Nerreter, K Martin Kortüm, José A Pérez-Simón, Hermann Einsele, Michael Hudecek, Sophia Danhof
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. Leukemia 35 (1) (2020)
Thomas Nerreter, Sebastian Letschert, Ralph Götz, Sören Doose, Sophia Danhof, Hermann Einsele, Markus Sauer, Michael Hudecek
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T. Nature communications 10 (1) (2019)
Hardikkumar Jetani, Irene Garcia-Cadenas, Thomas Nerreter, Simone Thomas, Julian Rydzek, Javier Briones Meijide, Halvard Bonig, Wolfgang Herr, Jordi Sierra, Hermann Einsele, Michael Hudecek
CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia 32 (5) (2018)
J Lohmeyer, Thomas Nerreter, J Dotterweich, H Einsele, R Seggewiss-Bernhardt
Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner. Clinical and experimental immunology 193 (1) (2018)